CHILDRENS CANCER GROUP

在这个捐赠周期中，费城儿童医院(CHOP)将继续其过去30年对CCG的捐赠。具体地说，CHOP将让大量患者参与治疗试验，勤奋地为生物和翻译研究提供患者样本，开展机构研究和与CCG相关的先导研究，并提供广泛而多样的年轻和成熟人才和科学领导力。在过去的周期中，CHOP的神经肿瘤学先导研究是4个CCG第一阶段和第二阶段研究的模板。在这个周期中，神经肿瘤学计划将引入新的传递途径，靶向治疗，以及探索1型神经纤维瘤病(NF-1)，以探索遗传学和脑肿瘤的接口。与神经肿瘤学计划合作，神经母细胞瘤计划将开发用于诊断、预后和治疗的TRK受体组。基于CHOP试点研究，白血病小组将建议CCG对CNS复发和已建立的CNS疾病进行长期、减少剂量的颅脊照射，并将引入针对骨髓复发的重复诱导/再巩固策略。CCG支持的白血病CHOP实验室研究包括治疗相关白血病和婴儿白血病的遗传流行病学，以及儿童骨髓增生异常和骨髓增殖综合征。CHOP实体肿瘤小组对间隔压缩的先导性研究正在纳入下一阶段的尤因试验。T(2；13)和其他融合基因的聚合酶链式反应分析将用于检测微小残留病和开发靶向治疗。肿瘤学部新的实验治疗计划将研究独特的生物制剂，如非依赖人类白细胞抗原的TALL-104细胞系，靶向CEP-751的TRK，以及IGFR可溶性受体和反义IGF1受体。CHOPS过渡计划旨在成为幸存者后续行动的典范，促进良好的预防保健战略和良好的研究。第一项过渡性研究试图确定患有第二种恶性肿瘤的患者的易感遗传风险因素。CHOP和CCG的相互作用是双向的，对双方都是互惠互利的。

In this grant cycle, The Children's Hospital of Philadelphia (CHOP) will continue its previous 30 years of contributions to CCG. Specifically, CHOP will enter large numbers of patients on therapeutic trials, diligently supply patient samples for biologic and translational studies, carry out both institutional and CCG-linked pilot studies, and provide a vast and varied repetoire of young and mature talent and scientific leadership. In the past cycle, CHOP's Neuro-Oncology pilot studies were templates for 4 CCG Phase I and Phase II studies. In this cycle the Neuro-Oncology Program will introduce novel routes of delivery, targetted therapy, and exploration of neurofibromatosis type 1(NF-1) to probe the interface of genetics and brain tumors. In collaboration with the Neuro-Oncology Program, the Neuroblastoma Program will develop the TRK group of receptors for diagnosis prognosis and therapy. Based on CHOP pilot studies, the Leukemia Group will propose to CCG protracted, reduced-dose craniospinal irradiation of CNS relapse and established CNS disease and will introduce the repetitive reinduction/reconsolidation strategy for marrow relapse. CCG- supported CHOP laboratory investigation in leukemia includes genetic epidemiology of treatment-related leukemias and infant leukemia and the pediatric myelodysplastic and myeloproliferative syndromes. The CHOP Solid Tumor Group's pilot study of interval compression is being incorporated into the next phase III Ewing's trial. PCR analysis of t(2;13) and other fusion genes will be used for detection of minimal residual disease and for development of targetted therapy. The Division of Oncology's new Experimental Therapeutics Program will investigate unique biologics such as the HLA independent TALL-104 cell line, TRK targetted CEP-751, and IGFR soluble receptor and antisense the IGF1 receptor. CHOPs Transition Program aims to be a prototype for follow-up of survivors, promoting good preventive health strategies and good research. The first transition study seeks to define predisposing genetic risk factors in patients who have second malignant neoplasms. The interactions of CHOP and CCG are bidirectional and are mutually rewarding for both.